Tranexamic Acid

# tranexamic acid ## Overview - **Classification**: Antifibrinolytic agent. - **Mechanism**: Reversibly binds to plasminogen, blocking its activation to plasmin. This prevents fibrin degradation, stabilizing existing clots. ## Primary Indications 1. **Menorrhagia**: Treatment of heavy menstrual bleeding. 2. **Short-term hemorrhage**: Prophylaxis and treatment in hemophilia patients (e.g., dental extractions). 3. **Trauma-induced hemorrhage**: Early administration in actively bleeding trauma patients. 4. **Hereditary angioedema (HAE)**: Prophylaxis of attacks. 5. **Postpartum hemorrhage (PPH)**: Adjunct to usual PPH management. ## Adult Dosing ### Standard Dosing **Menorrhagia** - **Dose**: Oral **1300 mg** (two 650 mg tablets) - **Frequency**: **TID** (three times daily) - **Route**: Oral - **Duration**: Up to **5 days** during menstruation. **Short-term Hemorrhage (e.g., Hemophilia)** - **Dose**: **10-15 mg/kg** - **Frequency**: **2-3 times daily** - **Route**: IV or Oral - **Duration**: **2-8 days** post-procedure/event. **Trauma-induced Hemorrhage** - **Dose**: **1 g** (loading dose) over **10 minutes** - **Frequency**: Followed by **1 g** IV infusion over **8 hours**. - **Route**: IV - **Special Considerations**: Administer within **3 hours** of injury. **Hereditary Angioedema (HAE)** - **Dose**: Oral **1000 mg** to **1500 mg** - **Frequency**: **2-3 times daily** - **Route**: Oral - **Duration**: Long-term prophylaxis. **Postpartum Hemorrhage (PPH)** - **Dose**: **1 g** over **10 minutes** - **Frequency**: Can repeat **1 g** if bleeding persists after 30 min or restarts within 24 hours. - **Route**: IV - **Special Considerations**: Administer within **3 hours** of delivery. ### Dose Adjustments - **Renal Impairment**: Requires dose reduction. - **CrCl 50-80 mL/min**: **Half** the usual dose. - **CrCl 10-50 mL/min**: **One-quarter** the usual dose. - **CrCl <10 mL/min**: **One-eighth** the usual dose. - **Hepatic Impairment**: No specific dose adjustment recommended. - **Elderly Patients**: Use with caution; monitor renal function due to age-related decline. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not routinely recommended due to limited data. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use only in life-threatening situations where benefits outweigh risks. Closely monitor for adverse effects. ### Infants (1-12 months) - **Dose**: **10-15 mg/kg** - **Frequency**: **Every 6-8 hours** - **Route**: IV - **Maximum**: **100 mg/kg/day** or **1 g/dose**, whichever is less. - **Special Notes**: Consider oral formulation if appropriate and available. ### Children (1-12 years) - **Dose**: **10-20 mg/kg** - **Frequency**: **Every 8 hours** - **Route**: IV or Oral - **Maximum**: **1 g/dose** IV, **1.5 g/dose** Oral. Max **30 mg/kg/day** or **6 g/day**. - **Special Notes**: Oral doses often rounded to nearest available tablet strength. ### Adolescents (13-18 years) - **Dose**: Generally **adult dosing** applies. - **Frequency**: According to specific adult indications. - **Route**: IV or Oral. - **Maximum**: **Adult maximum doses**. - **Special Notes**: Assess renal function. ## Safety Information ### Contraindications - **Absolute**: Active intravascular clotting (e.g., DIC with fibrinolytic activation). - **Absolute**: Subarachnoid hemorrhage (risk of cerebral edema/infarction). - **Absolute**: History of thrombosis or thromboembolic disease (DVT, PE, stroke) without concurrent anticoagulation. - **Absolute**: Acquired color vision impairment (oral). - **Absolute**: Hypersensitivity to tranexamic acid. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, diarrhea. - **Common (1-10%)**: Dizziness, headache, hypotension (with rapid IV), fatigue, allergic dermatitis. - **Serious but Rare**: Thromboembolic events (DVT, PE, MI, stroke), severe allergic reactions, visual disturbances. ### Key Drug Interactions - **Oral Contraceptives/Estrogens**: Increased risk of thrombosis. Consider alternatives. - **Factor IX complex concentrates/Anti-inhibitor coagulant complex**: Increased risk of thrombosis. Monitor closely. - **Thrombolytic agents (e.g., alteplase)**: Antagonistic effect. Avoid concurrent use. ## Monitoring & Follow-up - **Before Treatment**: Assess renal function (CrCl), baseline coagulation profile if indicated. - **During Treatment**: Monitor for signs/symptoms of thrombosis (pain, swelling, dyspnea). - **During Treatment**: Monitor for visual changes with long-term oral use (ophthalmologic exams). - **Clinical Signs**: Watch for excessive bleeding/re-bleeding, allergic reactions. - **IV Administration**: Monitor blood pressure; rapid infusion can cause hypotension. ## Clinical Pearls - 💡 **Tip 1**: Administer IV tranexamic acid slowly over **10 minutes** to avoid hypotension. - 💡 **Tip 2**: For trauma, administer within **3 hours** of injury; efficacy significantly decreases after this window. - 💡 **Tip 3**: Oral tranexamic acid for menorrhagia is taken only during menstruation, not continuously. - 💡 **Tip 4**: Discontinue immediately if visual disturbances, thromboembolic events, or severe allergic reactions occur. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.